FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add Arbuckle S	lress of Reporting <u>tuart A</u>	$ \underline{\mathbf{v}} $	ERTEX PHAR					ationship of Reportin k all applicable) Director	wner					
/Lact)	(Eirct)	(Middle)	<u>N</u>	<u>MA</u> [VRTX]				X	Officer (give title below)	Other below	(specify			
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED				Date of Earliest Transa 1/05/2018	action (N	/lonth/	Day/Year)		EVP\Chief Commercial Officer					
50 NORTHERN AVENUE				. If Amendment, Date of	Origina	l Filed	I (Month/Day/		6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOSTON MA 02210									X	Form filed by One Form filed by Mo Person				
(City)	(State)	(Zip)												
		Table I - No	n-Derivativ	e Securities Acq	uired	, Dis	posed of,	or Ber	neficially	Owned				
Date			2. Transaction Date (Month/Day/Ye	Execution Date,	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111501.4)			
Common Stock			11/05/201	.8	M		4,250	A	\$109.14	51,002	D			
Common Stoc	k		11/05/201	.8	S ⁽¹⁾		4,250	D	\$172.08	46,752	D			
Common Stoc	k	•	11/05/201	.8	M		1,553	Α	\$86.52	48,305	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$109.14	11/05/2018		M		4,250		(2)	02/02/2025	Common Stock	4,250	\$0.00	4,250	D	
Stock Option (Right to Buy)	\$86.52	11/05/2018		M		1,553		(3)	02/02/2027	Common Stock	1,553	\$0.00	13,980	D	

Explanation of Responses:

Common Stock

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Arbuckle's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. The option vests in 16 quarterly installments from 02/03/2015.
- 3. The option vests in 16 quarterly installments from 02/03/2017.

Remarks:

/s/ Omar White, Attorney-in-

11/06/2018

Fact

** Signature of Reporting Person

Date

140

401(k)

Ι

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.